Claudia Zierold

Claudia Zierold

Auto-generated profile, based on publicly available information

Claudia Zierold

DiaSorin

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 1998 in Analytical Biochemistry
Verified
Journal Article
Closed access
NANancy C. Arbour
Nancy C. Arbour
TRTroy K. Ross
Troy K. Ross
CZClaudia Zierold
Claudia Zierold
JPJean M. Prahl
Jean M. Prahl
HDHector F. DeLuca
Hector F. DeLuca

1 November 2016 in The Journal of Steroid Biochemistry and Molecular Biology
Verified
Journal Article
Open access
AVAndre Valcour
Andre Valcour
CZClaudia Zierold
Claudia Zierold
APAngela L. Podgorski
Angela L. Podgorski
GOGregory T. Olson
Gregory T. Olson
JWJohn V. Wall
John V. Wall
FBFabrizio Bonelli
Fabrizio Bonelli
1,25-Dihydroxyvitamin D (1,25-(OH)2D), the hormonal form of vitamin D, is difficult to measure because of its low circulating levels (pg/mL), and similarity to more abundant metabolites. Here a fully-automated chemiluminescent assay that accurately and precisely measures 1,25-(OH)2D is described. The novel 1,25-(OH)2D assay was conceived based on four pillars: (1) the VDR's ligand binding domain (LBD) as a capture molecule; (2) reaction conditions wherein 1,25-(OH)2D favors binding to LBD vs. the vitamin D binding protein; (3) exploitation of liganded-LBD's conformational change; (4) a monoclonal antibody specific to liganded-LBD. This specific, conformational, sandwich approach, unique for automated measurement of haptens, is superior to more cumbersome, conventional competitive formats. Accuracy of the 1,25-(OH)2D assay was corroborated by its alignment against LC-MS/MS with fit Deming regression equations of y=0.98x + 1.93 (r=0.92), and y=1.07x+3.77 (r=0.94) for different methods from Endocrine Sciences, Laboratory Corporation of America® and the University of Washington, respectively. Good analytical precision was manifested by its low estimated limit of quantitation (1.57pg/mL), average intra-assay imprecision (3.5%CV; range 1.1-4.7%), and average inter-assay imprecision (4.5%CV; range 3.4-7.2%). Expected and measured recovery values were congruent (93.4% mean). The novel 1,25-(OH)2D method exhibited excellent correlation with well validated LC-MS/MS assays from two laboratories. Significantly, its 65min turn-around time is quicker, and sample volume smaller (75μl) than current methods.

1 January 2020 in BioMed Research International
Verified
Journal Article
Open access
PDF file
AOAntone R Opekun
Antone R Opekun
CZClaudia Zierold
Claudia Zierold
ARAshli Rode
Ashli Rode
FBFrank A Blocki
Frank A Blocki
GFGiulia Fiorini
Giulia Fiorini
FSFred M Sutton
Fred M Sutton
Background. Antigens derived from Helicobacter pylori can be used as stool biomarkers to assist in the diagnosis of H. pylori infection. Since current assays have variable performance, we assessed the clinical performance of the automated LIAISON® Meridian H. pylori SA chemiluminescent immunoassay against more invasive biopsy tests that are considered to be the “gold standard” (Composite Reference Method). Methods. This prospective multisite study enrolled patients undergoing an esophagogastroduodenoscopy with collection of biopsy and stool specimens. Adult patients (≥22 years) participated in the study from February 2017 to August 2018. Specimens of the stomach were tested by three methods, known as the Composite Reference Method: (1) histological evaluation, (2) culture of the organism, and (3) rapid urease detection test. H. pylori in stool was detected using the automated LIAISON® Meridian H. pylori SA assay, a chemiluminescent immunoassay. Statistical analyses were performed using MedCalc 18.11.6. Results. 277 patients (63% female) were included in the study. The prevalence of infected subjects was 24.2% in this study cohort. Clinical performance assessed against the Composite Reference Method showed very good agreement (Cohen’s kappa = 0.922), with good sensitivity (95.5%) and specificity (97.6%). Reproducibility study results showed total imprecision ranging from 3.1% to 13.9% CV. Conclusion. The automated LIAISON® Meridian H. pylori SA assay brings reliable noninvasive testing for H. pylori to the laboratory that is in very good agreement with the current, more invasive biopsy‐based methods such as histology, culture, or rapid urease test. The clinical trial identifiers are NCT03060746 (pretherapy) and NCT03060733 (posttherapy).

4 July 2022 in United European Gastroenterology Journal
Verified
Journal Article
Open access
GFGionata Fiorino
Gionata Fiorino
SDSilvio Danese
Silvio Danese
LPLaurent Peyrin‐Biroulet
Laurent Peyrin‐Biroulet
MSMiquel Sans
Miquel Sans
FBFabrizio Bonelli
Fabrizio Bonelli
AMAlberto Malesci
Alberto Malesci
Introduction: Fecal calprotectin (FC) is established as a diagnostic marker to differentiate between inflammatory bowel diseases and non‐inflammatory conditions. Furthermore, it may be effective in monitoring response to treatment, and to predict relapse during maintenance therapy.Design: This was a prospective longitudinal study carried out in Italy, France and Spain. The primary objective was to correlate the LIAISON® Calprotectin assay measurements to quiescent ulcerative colitis (UC) or relapse as assessed by clinical data. Patients were assessed every 3 months for 12 months, and at 18 months.Results: The last FC measured prior to relapse was the variable that predicted relapse in a statistically significant manner. With a 62.3 μg/g cut‐off the area under the curve was 0.619, and the sensitivity was 62.9% (95% Confidence Interval [CI] 44.9%–78.5%) and specificity 63.0% (95% CI 53.1%–72.1%). Using machine learning methods, the last FC measurement was shown to have the largest impact in predicting relapse. An algorithm was developed that included other variables available following a clinician's visit, which resulted in an area under the curve of 0.754 for predicting relapse.Conclusion: In the present study FC measured by the LIAISON® Calprotectin assay on the visit before relapse is predictive of relapse in patients with quiescent UC. In a proof of concept, the accuracy of prediction can further be improved including other variables in an algorithm developed by machine learning.Trial registration: The trial is registered at clinicaltrials.gov with reference number NCT05168917.

20 May 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
FBFabrizio Bonelli
Fabrizio Bonelli
ASAntonella Sarasini
Antonella Sarasini
CZClaudia Zierold
Claudia Zierold
MCMariella Calleri
Mariella Calleri
ABAlice Bonetti
Alice Bonetti
Fausto BaldantiFausto Baldanti
Fausto Baldanti
BACKGROUND: In the Covid-19 pandemic, highly selective serological testing is essential to define exposure to SARS-CoV-2 virus. Many tests have been developed, yet with variable speed to first result, and of unknown quality, particularly when considering the prediction of neutralizing capacity. OBJECTIVES/METHODS: The LIAISON ® SARS-CoV-2 S1/S2 IgG assay was designed to measure antibodies against the SARS-CoV-2 native S1/S2 proteins in a standardized automated chemiluminescent assay. Clinical and analytical performance of the test were validated in an observational study using residual samples (>1500) with positive or negative Covid-19 diagnosis. RESULTS: The LIAISON ® SARS-CoV-2 S1/S2 IgG assay proved highly selective and specific, and offers semiquantitative measures of serum or plasma levels of anti-S1/S2 IgG with neutralizing activity. The diagnostic sensitivity was 91.3% and 95.7% at >5 or ≥15 days from diagnosis respectively, and 100% when assessed against a neutralizing assay. The specificity ranged between 97% and 98.5%. The average imprecision of the assay was <5 % coefficient of variation. Assay performance at 2 different cut-offs was evaluated to optimize predictive values in settings with different % disease prevalence. CONCLUSIONS. The automated LIAISON ® SARS-CoV-2 S1/S2 IgG assay brings efficient, sensitive, specific, and precise serological testing to the laboratory, with the capacity to test large amounts of samples per day: first results are available within 35 minutes with a throughput of 170 tests/hour. The test also provides a semiquantitative measure to identify samples with neutralizing antibodies, useful also for a large scale screening of convalescent plasma for safe therapeutic use. IMPORTANCE: With the worldwide advance of the COVID-19 pandemic, efficient, reliable and accessible diagnostic tools are needed to support public health officials and healthcare providers in their efforts to deliver optimal medical care, and articulate sound demographic policy. DiaSorin has developed an automated serology based assay for the measurement of IgG specific to SARS CoV-2 Spike protein, and tested its clinical performance in collaboration with Italian health care professionals who provided access to large numbers of samples from infected and non-infected individuals. The assay delivers excellent sensitivity and specificity, and is able to identify samples with high levels of neutralizing antibodies. This will provide guidance in assessing the true immune status of subjects, as well as meeting the pressing need to screen donors for high titer convalescent sera for subsequent therapeutic and prophylactic use.

4 October 2025 in Respiratory Investigation
Verified
Journal Article
Open access
SFSerena Ferraiuolo
Serena Ferraiuolo
FEFarah Bou Nasser Eddine
Farah Bou Nasser Eddine
DFDeborah Ferrante
Deborah Ferrante
ACAndrea Dal Corso
Andrea Dal Corso
LQLorenzo Querin
Lorenzo Querin
PIPaolo Ingallinella
Paolo Ingallinella
Legionella pneumophila is a leading cause of Legionnaires' disease, with Legionella pneumophila serogroup 1 (Lp1) being the most commonly detected strain. Current urinary antigen tests (UAT) primarily target Lp1, leading to underdiagnosis of non-Lp1 and other Legionella species. A broad-spectrum, fully automated UAT is needed to improve diagnostic accuracy and patient outcomes. A novel chemiluminescence immunoassay-based UAT was developed targeting both Legionella peptidoglycan-associated lipoprotein (PAL) and soluble lipopolysaccharide antigen to enable broader detection. Monoclonal antibodies were generated against PAL and integrated into an automated immunoassay platform. The assay's analytical performance was evaluated using recombinant PAL antigens, urine samples spiked with Legionella strains, and clinical specimens. Sensitivity, specificity, cross-reactivity, interference, and precision were assessed. The LIAISON® Legionella Urinary Ag assay demonstrated a 97.5 % positive agreement and 100 % negative agreement with the Binax™ UAT in detecting Legionella infections. Importantly, the new test also identified multiple non-Lp1 Legionella species, which the comparator assay failed to detect. The assay showed low imprecision, no cross-reactivity or interference. The LIAISON® Legionella Urinary Ag Assay, a fully automated chemiluminescence-based UAT, provides highly sensitive and specific detection of Legionella infections, including non-Lp1 strains, addressing a major limitation of existing diagnostics. This assay has the potential to improve early detection, guide targeted antibiotic therapy, and enhance public health surveillance of Legionnaires' disease.